Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Arrowhead Research   /   Forum Arrowhead Research geopend

Aandeel Arrowhead Pharmaceuticals OTC:ARWR.Q, US04280A1007

Vertraagde koers (usd) Verschil Volume
21,050   0,000   (0,00%) Dagrange 0,000 - 0,000 1.655   Gem. (3M) 1,2M

Forum Arrowhead Research geopend

Volgen
8.610 Posts
Pagina: «« 1 2 3 4 5 6 ... 431 »» | Laatste | Omlaag ↓
  2. drulletje drie 16 november 2018 09:06
    2019 will be productive

    Expect 2 new CTAs
    • ARO-HIF2
    • ARO-ENaC
    • Expect to be in Phase 2 or later with 3 wholly-owned candidates
    • ARO-AAT, ARO-ANG3, ARO-APOC3
    • Expect progress with partnered clinical candidates
    • ARO-HBV, AMG 890
    • Wildcards
    • New Janssen targets
    • Amgen undisclosed CV target
    • Muscle targeting
    • ARWR breakthroughs

    ir.arrowheadpharma.com/static-files/a...

  5. drulletje drie 20 november 2018 15:49
    quote:

    Roofer schreef op 20 november 2018 15:46:

    Flinke dalingen recentelijk.

    Mogelijkheid voor rebounce naar 17$ juist, of wachten tot de $10,-?

    Ik snap niet zo goed waarom, lijkt mij een fundament liggen dankzij J&J.
    Heb je de rest van de markten gezien laatste dagen?
    Dan snap ik wel waarom hoor! Ook de bio gaat dan gewoon mee omlaag dus geen idee hoever het nog kan dalen! J&J is een mooi bericht maar zullen gewoon goede onderzoeksresultaten moeten komen om de $ 20.00 plus op de borden te krijgen.
  11. forum rang 10 DeZwarteRidder 17 december 2018 18:02
    Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00

    Posted by Lisa Matthews on Dec 17th, 2018

    Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price upped by stock analysts at Cantor Fitzgerald from $145.00 to $165.00 in a report issued on Monday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock.

    Other equities analysts have also issued reports about the company. Chardan Capital reiterated a “buy” rating and issued a $24.50 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday. B. Riley upgraded Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $19.00 in a research note on Thursday, September 6th. William Blair reiterated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. Finally, Jefferies Financial Group lifted their price objective on Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 14th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $44.86.
    Get Arrowhead Pharmaceuticals alerts:

    Shares of Arrowhead Pharmaceuticals stock traded down $0.11 during trading on Monday, reaching $14.21. The company’s stock had a trading volume of 235,649 shares, compared to its average volume of 1,321,183. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.37 and a current ratio of 6.37. The firm has a market capitalization of $1.32 billion, a PE ratio of -21.86 and a beta of 2.05. Arrowhead Pharmaceuticals has a one year low of $3.08 and a one year high of $22.39.

    Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 11th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $11.26 million for the quarter, compared to analyst estimates of $3.73 million. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. Research analysts forecast that Arrowhead Pharmaceuticals will post 1.34 earnings per share for the current year.

    In related news, CEO Christopher Richard Anzalone sold 90,000 shares of the business’s stock in a transaction dated Wednesday, December 12th. The stock was sold at an average price of $14.07, for a total transaction of $1,266,300.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Peter Brian Leone sold 131,137 shares of the business’s stock in a transaction dated Friday, October 19th. The shares were sold at an average price of $13.49, for a total value of $1,769,038.13. Following the transaction, the vice president now owns 160,000 shares in the company, valued at $2,158,400. The disclosure for this sale can be found here. Insiders sold 305,637 shares of company stock worth $4,246,343 over the last quarter. 4.60% of the stock is currently owned by corporate insiders.

    A number of institutional investors and hedge funds have recently modified their holdings of ARWR. RTW Investments LP increased its stake in Arrowhead Pharmaceuticals by 184.6% during the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock valued at $112,874,000 after acquiring an additional 5,382,981 shares during the period. BlackRock Inc. increased its stake in Arrowhead Pharmaceuticals by 108.1% during the second quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after acquiring an additional 3,679,986 shares during the period. FMR LLC bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at about $37,922,000. Northern Trust Corp increased its stake in Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock valued at $14,464,000 after acquiring an additional 841,982 shares during the period. Finally, First Manhattan Co. increased its stake in Arrowhead Pharmaceuticals by 11.6% during the third quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock valued at $96,883,000 after acquiring an additional 523,675 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
  16. nelis h 7 januari 2019 14:44
    2 PB's die doen vermoeden dat het met de longterm Tox wel snor zit:

    Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

    Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

    ir.arrowheadpharma.com/press-releases
8.610 Posts
Pagina: «« 1 2 3 4 5 6 ... 431 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee